IP Library Granted Patent US 7,169,792
Granted Patent B2
US 7,169,792 · App. 10/496,809 · Granted Jan 30, 2007

Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic

Assignee: LG Life Sciences Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,792
App. No.
10/496,809
Granted
Jan 30, 2007
Kind
B2
Abstract

The present invention relates to a method of treating anti-bacterial infections which method comprises the separate, simultaneous or sequential administration to a patient in need thereof, of an effective amount of gemifloxacin or a salt thereof and a β-lactam antibiotic.

Claims (9)

1. A method of treating bacterial infections caused by at least one of Pseudomonas aeruginosa, E. faecalis and E. coli , which method comprises

simultaneous or sequential administration to a patient in need thereof, of a synergistic amount of gemifloxacin or a salt thereof and at least one cephalo-sporin selected from the group consisting of cefotaxime, ceflacor and ceftazidime.

2. The method according to claim 1 , wherein said gemifloxacin is gemifloxacin mesylate.

3. The method according to claim 1 , wherein the cephalo-sporin is cefotaxime.

4. The method according to claim 1 , wherein the cephalo-sporin is ceftazidime.

5. The method according to claim 1 , wherein gemifloxacin or a salt thereof and cephalo-sporin are administered in a ratio of from about 10:1 to about 1:10 (W/W).

6. The method according to claim 1 , in which of gemifloxacin or a salt thereof and cephalo-sporin are administered simultaneously.

7. The method according to claim 6 , achieved by the co-administration of separate compositions comprising gemifloxacin or a salt thereof and a cephalo-sporin.

8. The method according to any one of claims 1 , 2 , 3 , 4 or 6, wherein the bacterial infection is caused by Pseudomonas aeruginosa.

Assignments (2)
MERGER Recorded Sep 2, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043475/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2006
From: NICONOVICH, NANCY; RITTENHOUSE, STEPHEN; MCCLOSKEY, LYNN; PAEK, KYONG-SOOK; KIM, MU-YONG; YOUN, HA-SIK
To: LG LIFE SCIENCES LTD.
Reel/Frame 018660/0713 →
Continuity (1)
Related Publication 20050148571A1 · Jul 7, 2005